Effects of PCSK9 inhibitors on cancer, diabetes, and cardiovascular diseases

被引：0

作者：

Nejabat, Mojgan ^{[1
]}

Hadizadeh, Farzin ^{[2
]}

Almahmeed, Wael ^{[3
]}

Sahebkar, Amirhossein ^{[4
,5
]}

机构：

[1] Mashhad Univ Med Sci, Sch Pharm, Dept Med Chem, Mashhad, Iran

[2] Mashhad Univ Med Sci, Pharmaceut Technol Inst, Biotechnol Res Ctr, Mashhad, Iran

[3] Cleveland Clin Abu Dhabi, Heart & Vasc Inst, Abu Dhabi, U Arab Emirates

[4] Saveetha Univ, Saveetha Med Coll & Hosp, Saveetha Inst Med & Tech Sci, Ctr Global Hlth Res, Chennai, India

[5] Mashhad Univ Med Sci, Appl Biomed Res Ctr, Mashhad, Iran

来源：

DRUG DISCOVERY TODAY | 2025年 / 30卷 / 03期

关键词：

proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9i); diabetes; cancer; cardiovascular; cerebrovascular; stroke; LDL-CHOLESTEROL; METAANALYSIS; PREVENTION; EFFICACY; THERAPY; PEOPLE; SAFETY; RISK; ERA;

D O I：

10.1016/j.drudis.2025.104316

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9i) have potential applications in cancer therapy and as cholesterol-lowering treatments. The impact of PCSK9 suppression on both tumor growth and metastasis, as well as the management of diabetes, has been demonstrated. PCSK9i can also enhance outcomes and reduce cardiovascular (CV) events in individuals with a history of such events. In this review, we provide insights into the pharmacology, safety, and impact of PCSK9i. We highlight cutting-edge investigations, the development of innovative PCSK9i-based products, and a more comprehensive understanding of the potential effects of these drugs on cancer, diabetes, and CV and cerebrovascular diseases.

引用

页数：15

共 50 条

[1] A Review of PCSK9 Inhibitors and their Effects on Cardiovascular Diseases
Chen, Bo
Shi, Xin
Cui, Yanping
Hou, Aiping
Zhao, Pengjun
CURRENT TOPICS IN MEDICINAL CHEMISTRY, 2019, 19 (20) : 1790 - 1817
[2] Novel PCSK9 Inhibitors for Treating Cardiovascular Diseases
Sabnis, Ram W.
ACS MEDICINAL CHEMISTRY LETTERS, 2024, 15 (04): : 443 - 444
[3] Economic Evaluation of the PCSK9 Inhibitors in Prevention of the Cardiovascular Diseases
Parth Shah
Current Cardiology Reports, 2018, 20
[4] Economic Evaluation of the PCSK9 Inhibitors in Prevention of the Cardiovascular Diseases
Shah, Parth
CURRENT CARDIOLOGY REPORTS, 2018, 20 (07)
[5] PCSK9 in Haemostasis and Thrombosis: Possible Pleiotropic Effects of PCSK9 Inhibitors in Cardiovascular Prevention
Paciullo, Francesco
Momi, Stefania
Gresele, Paolo
THROMBOSIS AND HAEMOSTASIS, 2019, 119 (03) : 359 - 367
[6] PCSK9 inhibitors and cardiovascular outcomes
Steffens, Daniel
Bramlage, Peter
Scheeff, Celine
Kasner, Mario
Hassanein, Adel
Friebel, Julian
Rauch-Kroehnert, Ursula
EXPERT OPINION ON BIOLOGICAL THERAPY, 2020, 20 (01) : 35 - 47
[7] PCSK9 Inhibitors and Cardiovascular Events
Goemann, Iuri M.
Londero, Thiza M.
Dora, Jose M.
NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (08): : 773 - 774
[8] PCSK9 inhibitors and diabetes risk
Mueller-Wieland, Dirk
DIABETOLOGIE UND STOFFWECHSEL, 2018, 13 (02) : 140 - 141
[9] PCSK9 INHIBITORS FOR THE PREVENTION OF CARDIOVASCULAR DISEASE
Knijnik, Leonardo M.
Rivera, Manuel
Cardoso, Rhanderson
Fernandes, Gilson
Fernandes, Amanda
Orringer, Carl
Cohen, Mauricio
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2019, 73 (09) : 41 - 41
[10] PCSK9 Inhibitors: Potential in Cardiovascular Therapeutics
Do, Rose Q.
Vogel, Robert A.
Schwartz, Gregory G.
CURRENT CARDIOLOGY REPORTS, 2013, 15 (03)

← 1 2 3 4 5 →